Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.

MLA

Webb, Mason, et al. “Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma.” Journal of Clinical Oncology, vol. 41, June 2023, p. TPS2085. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS2085.

APA

Webb, M., Burns, T. C., Twohy, E., Sener, U., Kizilbash, S. H., Ruff, M. W., Uhm, J. H., Galanis, E., D’Andre, S. D., Riviere-Cazaux, C., Lee, B. H., Flickinger, L. M., Parney, I. F., & Campian, J. L. (2023). Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma. Journal of Clinical Oncology, 41, TPS2085. https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS2085

Chicago

Webb, Mason, Terry C Burns, Erin Twohy, Ugur Sener, Sani Haider Kizilbash, Michael W. Ruff, Joon H. Uhm, et al. 2023. “Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma.” Journal of Clinical Oncology 41 (June): TPS2085. doi:10.1200/JCO.2023.41.16_suppl.TPS2085.